Details for New Drug Application (NDA): 021252
✉ Email this page to a colleague
NDA 021252 describes CANASA, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the CANASA profile page.
The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
Summary for 021252
| Tradename: | CANASA |
| Applicant: | Abbvie |
| Ingredient: | mesalamine |
| Patents: | 2 |
Suppliers and Packaging for NDA: 021252
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252 | NDA | Allergan, Inc. | 58914-501 | 58914-501-33 | 3 SUPPOSITORY in 1 BOX (58914-501-33) |
| CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252 | NDA | Allergan, Inc. | 58914-501 | 58914-501-42 | 42 SUPPOSITORY in 1 BOX (58914-501-42) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUPPOSITORY;RECTAL | Strength | 500MG | ||||
| Approval Date: | Jan 5, 2001 | TE: | RLD: | No | |||||
Profile for product number 002
Complete Access Available with Subscription
